Effect of oral administration of 'essential' phospholipid, beta-glycerophosphate, and linoleic acid on biliary lipids in patients with cholelithiasis.
6 patients with radiolucent cholelithiasis underwent randomized successive 3-week trials on each of the following medications: beta-glycerophosphate, linoleic acid, or purified soybean lecithin. Bile-rich duodenal fluid was obtained prior to the study and following each treatment period. Soybean lecithin feeding effected a qualitative change in biliary lecithin with increased fatty acid unsaturation, but no significant improvement in biliary cholesterol saturation or lipid composition changes including a proportionate increase in biliary phospholipids resulted from any treatment program. A 6-month therapeutic trial with soybean lecithin plus cholic acid failed to show a therapeutic response indicative of gallstone dissolution in the 6 patients.
D000328:Adult; D000368:Aged; D001646:Bile / Q000032:analysis*; D001647:Bile Acids and Salts / Q000032:analysis; D002769:Cholelithiasis / Q000188:drug therapy*; D002784:Cholesterol / Q000032:analysis; D002793:Cholic Acids / Q000627:therapeutic use*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005069:Evaluation Studies as Topic; D005227:Fatty Acids / Q000032:analysis; D005260:Female; D005994:Glycerophosphates / Q000627:therapeutic use*; D006801:Humans; D008041:Linoleic Acids / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010713:Phosphatidylcholines / Q000032:analysis / Q000627:therapeutic use*; D010743:Phospholipids / Q000032:analysis; D013025:Glycine max
D001647:Bile Acids and Salts; D002793:Cholic Acids; D005227:Fatty Acids; D005994:Glycerophosphates; D008041:Linoleic Acids; D010713:Phosphatidylcholines; D010743:Phospholipids; D002784:Cholesterol